**APPENDIX A. Categorization of Infectious Problems**

|  |  |
| --- | --- |
| Group | Infectious Problems |
| Bacteremia | BacteremiaCentral-line associated blood stream infection |
| Bone and joint infection | MastoiditisOsteomyelitisSeptic arthritis |
| CNS infection | EncephalitisMeningitisVentriculoperitoneal infection |
| Febrile neutropenia | Febrile neutropeniaNeutropenia (no fever) |
| Gastrointestinal/IAI | AppendicitisAppendicitis with perforationIntra-abdominal process*C. difficile* infectionNecrotizing enterocolitis |
| Other | Atypical mycobacteriumEndocarditisLymphadenitisMediastinitisOmphalitisOrbital cellulitisSkin and soft tissue infectionRetropharyngeal abscessSurgical site infection |
| Prophylaxis | Postoperative prophylaxisPreoperative prophylaxisProphylaxis |
| Respiratory infection | Acute chest syndromeAspiration pneumoniaCommunity acquired pneumonia, uncomplicatedCommunity acquired pneumonia, complicatedCystic fibrosis exacerbationOtitis mediaPneumoniaPresumed respiratory infectionSinusitisTracheitisVentilator-associated pneumonia/hospital-associated pneumonia |
| Sepsis | Culture negative sepsisRule-out central-line associated blood stream infectionRule-out sepsisSepsis with multiorgan decompensationSepsis/septic shock |
| Urinary tract infection | Urinary tract infection |

**APPENDIX B. Categorization of Antimicrobial Agents**

|  |  |  |  |
| --- | --- | --- | --- |
| Broad Spectrum Gram-Positive  | Broad Spectrum Gram-Negative  | Narrow Spectrum  | Other |
| DaptomycinLinezolidVancomycin | Amoxicillin-clavulanateAmpicillin-sulbactamCefepimeCefotaximeCeftazidimeCeftriaxoneCefuroximeCiprofloxacinImipenemLevofloxacinMeropenemMoxifloxacinPiperacillin-tazobactamTigecycline | AmikacinAmoxicillinAmpicillinAzithromycinAztreonamCefazolinCefiximeCefoxitinCephalexinClindamycinDoxycyclineErythromycinGentamicinMetronidazoleNafcillinPenicillinRifampinSulfamethoxazole-trimethoprimTobramycin | AcyclovirAmphotericin deoxycholateAnidulafunginCaspofunginCidofovirFluconazoleFoscarnetGanciclovirLiposomal amphotericinMicafunginOseltamivirPosaconazoleValganciclovirVoriconazole |

**APPENDIX C. Categorization of Recommendation Type**

|  |  |
| --- | --- |
| Recommendation Type Group | Recommendation Type |
| Change agent | Broaden empiricallyChange antibiotic (availability)Change antibiotic based on culture/sensitivityNarrow based on culture/sensitivityNarrow empirically |
| Clarify | Clarify indication/plan |
| Duration modification | Duration suggestionLengthen durationShorten duration |
| IV to PO | IV to PO |
| No Change | No Change |
| Optimize dose or frequency | Decrease doseDecrease frequencyIncrease doseIncrease frequency |
| Other | ID ConsultLab monitoringOther |
| Stop | Stop (Consolidate to fewer agents)Stop (No indication)Stop (Redundant therapy) |

**APPENDIX D. Categorization of Provider Type Communicated Recommendation**

|  |  |  |
| --- | --- | --- |
| Infectious Diseases service | Pharmacist | Primary service |
| Infectious Diseases attendingInfectious Diseases fellow | PharmacistPharmacy resident | Advanced practice providerMedical fellowMedical residentNon-Infectious Diseases attending |